Banco Sabadell has led the first investment round of medtech company Thytech, which closed at €350,000. This marks the second investment under the fourth edition of the BStartup Health program, which received applications from 121 startups.

Thytech was founded by researchers from the Health Research Institute of Hospital General Universitario Gregorio Marañón (IISGM) in Madrid and has developed a world-pioneering cell therapy to prevent transplant rejection, according to a statement released by Banco Sabadell.

The investment is led by Banco Sabadell’s BStartup unit through its BStartup Health program, with participation from Genesis Biomed and private investors.

The innovation is based on the use of thyTreg cells, which have regulatory properties and are capable of controlling immune hyperactivation processes responsible for various serious and highly prevalent diseases.

Team leader Rafael Correa explained that although the results are still preliminary, “this strategy could open a new era in the treatment of many diseases associated with harmful inflammatory processes.”

More info: europapress.es